Eisai
Tracked across 21 events · 230 articles · First seen Apr 21, 2022 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Eisai is the primary actor, launching Leqembi in India, which could drive revenue growth and strengthen its position in the Alzheimer's treatment market.
Aug 03, 2026 · 6 articles
Business
Impact: Eisai, as the primary developer and commercializer of Lecanemab, presented the sales simulation, indicating strong future revenue growth for the company. This positively impacts its financial projections and market position.
May 25, 2026 · 7 articles
Tech
Impact: Eisai co-produces lecanemab (Leqembi), an anti-amyloid drug whose effectiveness was disputed by the Cochrane review, potentially leading to financial repercussions.
Apr 16, 2026 · 6 articles
Regulatory
Impact: Manufacturer of lecanemab; requested reconsideration leading to favorable recommendation, potentially increasing drug sales.
Jul 16, 2026 · 7 articles
Business
Impact: Eisai reported Leqembi sales of JPY 29.3 billion in Q2 2026, driving its revenue and partnership with Biogen.
Jul 29, 2026 · 6 articles
Business
Impact: Eisai's Eribulin Injection is the reference listed drug for the newly approved generic Eribulin Mesylate Injection, indicating potential competition and market share impact for Eisai.
Jun 03, 2026 · 8 articles
International
Impact: Eisai's stock tumbled and declined, contributing to the negative performance of some pharmaceutical companies.
May 18, 2026 · 23 articles
Tech
Impact: Key member; contributes to the consortium's research efforts.
Jul 13, 2026 · 6 articles
International
Impact: Eisai is expected to announce investments and collaborations in life sciences as part of the broader UK-Japan agreements.
Jun 13, 2026 · 26 articles
Business
Over the period from late July to early August 2026, the Japanese stock market experienced significant volatility, with the Nikkei 225 index swinging sharply between gains and losses. The market was influenced by mixed cues…
Impact: Eisai gained more than 3% on one day, reflecting gains.
Jul 24, 2026 · 37 articles
Business
The Japanese stock market experienced a significant rally over several trading sessions in August 2026, with the Nikkei 225 index surging to record levels above 68,000. The rally was driven by strong gains in technology…
Impact: Eisai declined almost 4%, underperforming the market.
Apr 21, 2022 · 26 articles
Tech
A nationwide Swedish observational study from Karolinska Institute, published in the European Heart Journal, found that patients with both atrial fibrillation and Alzheimer's disease who were treated with newer oral anticoagulants (NOACs) experienced a significantly…
Impact: Greta Duréel has consulted for Eisai, but no direct impact from this study.
Aug 12, 2026 · 6 articles
Business
Impact: Eisai is BioArctic's partner for Leqembi, responsible for regulatory interactions and commercialization globally, indicating a significant collaboration for BioArctic's key product.
May 28, 2026 · 9 articles
Business
Impact: Eisai is mentioned as BioArctic's partner in developing and commercializing Leqembi.
May 29, 2026 · 6 articles
Business
Impact: Eisai, in collaboration with Biogen, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
Business
BioArctic announced it will publish its second quarter report for April-June 2026 on August 26, 2026, at 8:00 a.m. CEST. The company invited investors, analysts, and media to a webcast and teleconference at 9:30 a.m.…
Impact: Eisai is BioArctic's partner for Leqembi commercialization. The Q2 report may include updates on Leqembi sales, but no specific impact is announced.
Aug 19, 2026 · 6 articles
Business
On August 19, 2026, BioArctic and Bicara Therapeutics announced a research collaboration agreement to develop a novel antibody-based treatment for glioblastoma, an aggressive brain cancer. The collaboration combines BioArctic's BrainTransporter technology with Mesenkia's KITAIbodies platform,…
Impact: Eisai is BioArctic's partner for Leqembi, but is not directly involved in this collaboration. The event does not materially affect Eisai.
Aug 19, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Eisai live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard